Darsalia Vladimer, Hua Sansan, Larsson Martin, Mallard Carina, Nathanson David, Nyström Thomas, Sjöholm Åke, Johansson Maria E, Patrone Cesare
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
PLoS One. 2014 Aug 7;9(8):e103114. doi: 10.1371/journal.pone.0103114. eCollection 2014.
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.
艾塞那肽-4是一种胰高血糖素样受体1激动剂,临床上用于治疗2型糖尿病,在实验性中风模型中也显示出神经保护作用。然而,虽然已经对中风前开始药物治疗时艾塞那肽-4的神经保护功效进行了深入研究,但中风后急性开始治疗时艾塞那肽-4的治疗潜力尚未明确确定。此外,尚未对正常和老年糖尿病小鼠的神经保护功效进行比较。最后,艾塞那肽-4功效背后的细胞机制仅得到了部分研究。本研究的主要目的是确定在临床相关情况下,中风后开始治疗时,艾塞那肽-4对正常和老年2型糖尿病小鼠的神经保护功效。此外,我们还对艾塞那肽-4对中风诱导的神经炎症的影响进行了表征。对2月龄健康小鼠和14月龄2型糖尿病/肥胖小鼠进行大脑中动脉闭塞手术。此后1.5、3或4.5小时腹腔注射5或50μg/kg艾塞那肽-4。持续治疗(0.2μg/kg/天)1周。通过测量梗死体积和对NeuN阳性神经元进行体视学计数来评估神经保护功效。通过对M1/M2小胶质细胞亚型和促炎细胞因子进行基因表达分析来确定神经炎症。我们发现,中风后1.5和3小时,50μg/kg艾塞那肽-4对年轻健康小鼠和老年糖尿病/肥胖小鼠均具有神经保护功效。5μg/kg剂量仅在1.5小时具有神经保护作用。艾塞那肽-4治疗对促炎标志物和M1表型没有影响,而M2标志物则显著上调。我们的结果支持在院前/早期住院环境中使用艾塞那肽-4来减少中风损伤,无论年龄/糖尿病情况如何。结果表明,小胶质细胞/巨噬细胞向M2修复性表型极化是神经保护的潜在机制。